Introduction/Background Many centers have switched to using a lower dose of cisplatin IP in an attempt to reduce toxicity and improve patient tolerance.

Methodology 60 patients were included in this prospective study with 20 cases with primary cytoreductive surgery (PCRS) and 40 cases underwent neoadjuvant chemotherapy followed by IDS (interval debulking surgery) basal CT and serum ca 125 was done before surgery along with CBC, LFT, RFT, CT and CA 125 was done after surgery as a base line the IP catheter was introduced during surgery through right upper abdominal quadrant if there is no more than 1 cm residual tumor half of patients received IP cisplatin 80 mg/m² with IV paclitaxel (group I) and the other half received 50 mg/m² with IV paclitaxel (group II) chemotherapy doses was given every 3 weeks for 3 cycles after completion of the cycles, we measured serum CA l25, performed CT and assessed the toxicity.

Results Most patients in our study were with stage III epithelial ovarian cancer. Serum CA l25 decreased significantly after chemotherapy nearly similar in both groups with no statistically significance between groups . toxicity was more in group I and was statistically significant regarding nephrotoxicity, neurotoxicity, nausea and vomiting and loss of appetite it was not significant regarding neutropenia. Catheter complications were observed in 17.3% of patients with no significant difference between both groups. The proportion of patients completing all cycles was 47% and 65.2% in group I and II respectively that was not statistically significant.

Conclusion The use of 50 mg/m² of cisplatin IP was associated with lower toxicity and same response when comparing with the use of 80 mg/m² of cisplatin IP and completeness of the cycles was better with the lower dose of IP cisplatin.

Disclosure Nothing to disclose.